The pattern of occurrence of malignant disorders in people with Down's syndrome (DS) is
unique and may serve as a model in the search for leukaemogenic genes and tumour …

Children with Down syndrome are at an elevated risk of leukemia, especially myeloid
leukemia (ML-DS). This malignancy is frequently preceded by transient abnormal …

A unique transient leukemia (TL) has been described in newborns with Down syndrome
(DS; or trisomy 21 mosaics). This leukemia has a high incidence of spontaneous remission; …

Children with Down syndrome (DS) have an increased risk for leukemia. The prognosis for
DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of …

To determine the epidemiology and outcome of children with Down syndrome (DS)
diagnosed with acute leukaemia in the Nordic countries, data registered in the Nordic …

Purpose: To determine the outcome of children with Down syndrome (DS) and acute
myeloid leukemia (AML) receiving standard timing chemotherapy without bone marrow …

It has been recognized that chromosomal abnormalities in childhood leukemia, are linked to
both leukemogenesis and segregate patients into prognostic treatment groups. This is best …

Purpose To evaluate a less intensive chemotherapeutic regimen specifically designed for
patients with Down syndrome (DS) and acute myeloid leukemia (AML), and to determine the …

Down syndrome children with acute megakaryocytic leukemia (AMkL) have higher cure
rates than non-Down syndrome acute myeloid leukemia (AML) patients treated with cytosine …

Learning Objectives Evaluate malignancies for which children with Down syndrome are at
increased and decreased risk in order to screen appropriately. Analyze the clinical and …